• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

    1.295 -0.065 (-4.78%)
    Streaming Delayed Price Updated: 10:42 AM EDT, May 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about VivoSim Labs, Inc. - Common Stock

    News headline image
    VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
    VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Announces Pricing of up to a $4 Million Public Offering
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
    ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
    Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with... 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
    Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
    JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
    Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    Roadzen Inc. (NASDAQ: RDZN) Accelerates U.S. Expansion with Strategic Acquisition – Surges on Record Volume – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
    Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market 
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    News headline image
    VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
    From VivoSim Labs, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.